Prediction of Alzheimer's disease biomarker status defined by the 'ATN framework' among cognitively healthy individuals: results from the EPAD longitudinal cohort study

被引:26
|
作者
Calvin, Catherine M. [1 ]
de Boer, Casper [2 ]
Raymont, Vanessa [1 ]
Gallacher, John [1 ]
Koychev, Ivan [1 ]
机构
[1] Univ Oxford, Dept Psychiat, Warneford Hosp, Oxford OX3 7JX, England
[2] Amsterdam UMC, Alzheimer Ctr Amsterdam, Amsterdam, Netherlands
基金
英国医学研究理事会;
关键词
ATN framework; Risk scores; White matter lesions volume; VASCULAR RISK-FACTORS; AA RESEARCH FRAMEWORK; DEMENTIA RISK; BIOLOGICAL DEFINITION; SERUM-CHOLESTEROL; PHYSICAL-ACTIVITY; MIDLIFE; PROFILE; PATHOLOGIES; VALIDATION;
D O I
10.1186/s13195-020-00711-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background The Amyloid/Tau/Neurodegeneration (ATN) framework has been proposed as a means of evidencing the biological state of Alzheimer's disease (AD). Predicting ATN status in pre-dementia individuals therefore provides an important opportunity for targeted recruitment into AD interventional studies. We investigated the extent to which ATN-defined biomarker status can be predicted by known AD risk factors as well as vascular-related composite risk scores. Methods One thousand ten cognitively healthy older adults were allocated to one of five ATN-defined biomarker categories. Multinomial logistic regression tested risk factors including age, sex, education, APOE4, family history of dementia, cognitive function, vascular risk indices (high systolic blood pressure, body mass index (BMI), high cholesterol, physical inactivity, ever smoked, blood pressure medication, diabetes, prior cardiovascular disease, atrial fibrillation and white matter lesion (WML) volume), and three vascular-related composite scores, to predict five ATN subgroups; ROC curve models estimated their added value in predicting pathology. Results Age, APOE4, family history, BMI, MMSE and white matter lesions (WML) volume differed between ATN biomarker groups. Prediction of Alzheimer's disease pathology (versus normal AD biomarkers) improved by 7% after adding family history, BMI, MMSE and WML to a ROC curve that included age, sex and APOE4. Risk composite scores did not add value. Conclusions ATN-defined Alzheimer's disease biomarker status prediction among cognitively healthy individuals is possible through a combination of constitutional and cardiovascular risk factors but established dementia composite risk scores do not appear to add value in this context.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Psychometric Evaluation of the Neuropsychological Test Battery in Individuals with Normal Cognition, Mild Cognitive Impairment, or Mild to Moderate Alzheimer's Disease: Results from a Longitudinal Study
    Harrison, J. E.
    Rentz, D. M.
    Brashear, H. R.
    Arrighi, H. M.
    Ropacki, M. T.
    Liu, E.
    JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2018, 5 (04): : 236 - 244
  • [42] Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study
    Reijs, Babette L. R.
    Vos, Stephanie J. B.
    Soininen, Hilkka
    Lotjonen, Jyrki
    Koikkalainen, Juha
    Pikkarainen, Maria
    Hall, Anette
    Vanninen, Ritva
    Liu, Yawu
    Herukka, Sanna-Kaisa
    Freund-Levi, Yvonne
    Frisoni, Giovanni B.
    Frolich, Lutz
    Nobilij, Flavio
    Rikkert, Marcel Olde
    Spiru, Luiza
    Tsolaki, Magda
    Wallinn, Asa K.
    Scheltens, Philip
    Verhey, Frans
    Visser, Pieter Jelle
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 60 (04) : 1387 - 1395
  • [44] No increased risk of Alzheimer's disease among people with immune-mediated inflammatory diseases: findings from a longitudinal cohort study of US older adults
    Booth, Michael J.
    Kobayashi, Lindsay C.
    Janevic, Mary R.
    Clauw, Daniel
    Piette, John D.
    BMC RHEUMATOLOGY, 2021, 5 (01)
  • [45] Hormone replacement therapy is associated with improved cognition and larger brain volumes in at-risk APOE4 women: results from the European Prevention of Alzheimer’s Disease (EPAD) cohort
    Rasha N. M. Saleh
    Michael Hornberger
    Craig W. Ritchie
    Anne Marie Minihane
    Alzheimer's Research & Therapy, 15
  • [46] Hormone replacement therapy is associated with improved cognition and larger brain volumes in at-risk APOE4 women: results from the European Prevention of Alzheimer's Disease (EPAD) cohort
    Saleh, Rasha N. M.
    Hornberger, Michael
    Ritchie, Craig W.
    Minihane, Anne Marie
    ALZHEIMERS RESEARCH & THERAPY, 2023, 15 (01)
  • [47] A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort
    Stamate, Daniel
    Kim, Min
    Proitsi, Petroula
    Westwood, Sarah
    Baird, Alison
    Nevado-Holgado, Alejo
    Hye, Abdul
    Bos, Isabelle
    Vos, Stephanie J. B.
    Vandenberghe, Rik
    Teunissen, Charlotte E.
    Ten Kate, Mara
    Scheltens, Philip
    Gabel, Silvy
    Meersmans, Karen
    Blin, Olivier
    Richardson, Jill
    De Roeck, Ellen
    Engelborghs, Sebastiaan
    Sleegers, Kristel
    Bordet, Regis
    Ramit, Lorena
    Kettunen, Petronella
    Tsolaki, Magda
    Verhey, Frans
    Alcolea, Daniel
    Lleo, Alberto
    Peyratout, Gwendoline
    Tainta, Mikel
    Johannsen, Peter
    Freund-Levi, Yvonne
    Frolich, Lutz
    Dobricic, Valerija
    Frisoni, Giovanni B.
    Molinuevo, Jose L.
    Wallin, Anders
    Popp, Julius
    Martinez-Lage, Pablo
    Bertram, Lars
    Blennow, Kaj
    Zetterberg, Henrik
    Streffer, Johannes
    Visser, Pieter J.
    Lovestone, Simon
    Legido-Quigley, Cristina
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2019, 5 (01) : 933 - 938
  • [48] No increased risk of Alzheimer’s disease among people with immune-mediated inflammatory diseases: findings from a longitudinal cohort study of U.S. older adults
    Michael J. Booth
    Lindsay C. Kobayashi
    Mary R. Janevic
    Daniel Clauw
    John D. Piette
    BMC Rheumatology, 5
  • [49] White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS)
    Eloyan, Ani
    Thangarajah, Maryanne
    An, Na
    Borowski, Bret J.
    Reddy, Ashritha L.
    Aisen, Paul
    Dage, Jeffrey L.
    Foroud, Tatiana
    Ghetti, Bernardino
    Griffin, Percy
    Hammers, Dustin
    Iaccarino, Leonardo
    Jack, Clifford R., Jr.
    Kirby, Kala
    Kramer, Joel
    Koeppe, Robert
    Kukull, Walter A.
    La Joie, Renaud
    Mundada, Nidhi S.
    Murray, Melissa E.
    Nudelman, Kelly
    Rumbaugh, Malia
    Soleimani-Meigooni, David N.
    Toga, Arthur
    Touroutoglou, Alexandra
    Atri, Alireza
    Day, Gregory S.
    Duara, Ranjan
    Graff-Radford, Neill R.
    Honig, Lawrence S.
    Jones, David T.
    Masdeu, Joseph
    Mendez, Mario F.
    Musiek, Erik
    Onyike, Chiadi U.
    Rogalski, Emily
    Salloway, Stephen
    Sha, Sharon
    Turner, Raymond S.
    Wingo, Thomas S.
    Wolk, David A.
    Womack, Kyle
    Beckett, Laurel
    Gao, Sujuan
    Carrillo, Maria C.
    Rabinovici, Gil
    Apostolova, Liana G.
    Dickerson, Brad
    Vemuri, Prashanthi
    ALZHEIMERS & DEMENTIA, 2023, 19 : S89 - S97
  • [50] Clinical Utility of an Alzheimer's Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study
    Monane, Mark
    Maraganore, Demetrius M.
    Carlile, Robert M.
    Johnson, Kim G.
    Merrill, David A.
    Gitelman, Darren R.
    Sharlin, Kenneth S.
    Vandevrede, Lawren A.
    George, Kristi K.
    Wang, Jimin
    West, Tim
    Jacobs, Leslie
    Verghese, Philip B.
    Braunstein, Joel B.
    DIAGNOSTICS, 2025, 15 (02)